Novartis wins FDA breakthrough therapy for AML treatment

February 19, 2016 3:22 PM

2 0

Novartis wins FDA breakthrough therapy for AML treatment

ZURICH – Novartis received breakthrough therapy designation from the U.S. Food and Drug Administration for an investigational treatment for newly-diagnosed FLT3-mutated acute myeloid leukemia, the Swiss drugmaker said on Friday.

Patients who received PKC412, also called midostaurin, combined with standard induction and consolidation chemotherapy experienced what Novartis called "a significant improvement in overall survival".

Also read: Senate Clears Bill to Ease FDA Drug and Device Approvals

Read more

To category page

Loading...